Sartorius strengthens product portfolio for cell and gene therapies by acquiring a majority stake in CellGenix
GTTINGEN, Germany, July 2, 2021 /PRNewswire/ -- The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH.
- GTTINGEN, Germany, July 2, 2021 /PRNewswire/ -- The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH.
- Sartorius has initially acquired 51 percent of this company, which has been privately owned until now, for around 100millioneuros in cash.
- At the beginning of 2023 and 2026, Sartorius plans to acquire the remaining shares of CellGenix.
- The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.